Cardinal Health has inaugurated its Advanced Therapy Innovation Center in La Vergne, Tennessee. The 8,000-square-foot facility, part of a larger distribution center, is designed to address the specialized logistics needs of cell and gene therapies.

“The opening of this new center is a testament to the growth we have seen with cell and gene therapies and the promise of their potential to impact patients,” said Fran Gregory, VP, Emerging Therapies. “Our investments in this space will have the potential to impact thousands of patients with rare diseases for which there are currently no or limited treatment options. We are excited to expand our capabilities to deliver treatments to patients that need them the most.”

The new center features deep-frozen storage, temperature-controlled shipping capabilities, and collaboration areas. It will also offer Advanced Therapy Connect, a unified ordering portal, and market access strategy consulting services.

“Many advanced therapies require specialized handling and temperature controls through the storage and shipping process to ensure their quality, safety and efficacy,” said Joel Wayment, VP/GM, 3PL Services and Packaging Solutions. “The Advanced Therapy Innovation Center will allow us to further support manufacturers – so that patients receive the treatments that they need when they need them.”

This investment positions Cardinal Health as a leading provider of logistics solutions for the cell and gene therapy industry, helping to ensure that patients receive these critical treatments in a timely and efficient manner.

Source:
https://www.contractpharma.com/contents/view_breaking-news/2024-08-28/cardinal-health-opens-new-advanced-therapy-center/9769
GMP mRNA
Check out our mRNA service to expedite your vaccine research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE